✦ LIBER ✦

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

✍ Scribed by Motzer, Robert J; Porta, Camillo; Vogelzang, Nicholas J; Sternberg, Cora N; Szczylik, Cezary; Zolnierek, Jakub; Kollmannsberger, Christian; Rha, Sun Young; Bjarnason, Georg A; Melichar, Bohuslav; De Giorgi, Ugo; Grünwald, Viktor; Davis, Ian D; Lee, Jae-Lyun; Esteban, Emilio; Urbanowitz, Gladys; Cai, Can; Squires, Matthew; Marker, Mahtab; Shi, Michael M; Escudier, Bernard

Book ID: 122526059
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 436 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(14)70030-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Axitinib versus sorafenib as first-line

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

✍ Hutson, Thomas E; Lesovoy, Vladimir; Al-Shukri, Salman; Stus, Viktor P; Lipatov, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 317 KB

Randomized Phase II Trial of First-Line

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

✍ Coplen, D.E. 📂 Article 📅 2009 🏛 Elsevier Science ⚖ 69 KB

Tivozanib Versus Sorafenib As Initial Ta

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

✍ Motzer, R. J.; Nosov, D.; Eisen, T.; Bondarenko, I.; Lesovoy, V.; Lipatov, O.; T 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 196 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

## Background: Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (folfiri) is unknow